Latest Verenium Corporation Stories
SAN DIEGO, Dec. 10, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the signing of a $22.5 million secured debt financing with the Athyrium Opportunities Fund ("Athyrium"). (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO) Net proceeds after estimated expenses will be approximately $21.3 million, providing Verenium with...
SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported operating highlights and financial results for the third quarter and nine months ended September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO) "During the third quarter we made some important steps forward with our manufacturing investment...
SAN DIEGO, Nov. 1, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2012 third quarter financial results on Thursday, November 8, 2012 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Thursday, November 8, 2012 at 5:00 p.m. ET. (Logo:...
SAN DIEGO, Oct. 8, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it has entered into an agreement with Comerica Bank for a two-year, $10 million revolving credit facility. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO) This credit facility will allow Verenium to borrow up to $8.4 million against eligible...
SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will host a live webcast of its Capital Markets Day for investors and analysts on Tuesday, October 9, 2012 in New York City. The webcasted presentations and Q&A will begin at 8:00 a.m. and are expected to conclude at 11:00 a.m. ET. (Logo:...
SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that members of its management team will be presenting at four upcoming conferences. James Levine, President and Chief Executive Officer, will present at the 2012 Modern Energy Forum in Denver, Colorado on Wednesday, September 5, 2012. The presentation is scheduled to...
SAN DIEGO, Aug. 6, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported operating highlights and financial results for the second quarter and six months ended June 30, 2012. "The first half of the year proved to be an important turning point for Verenium," said James Levine, President & Chief Executive Officer at Verenium. "With the...
SAN DIEGO, July 31, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that James Levine, President and Chief Executive Officer, will present at the upcoming Jefferies 2012 Global Industrial and Aerospace and Defense Conference. The presentation is scheduled to begin at 10:30 a.m. ET on Tuesday, August 7, 2012 and will take place in New York...
SAN DIEGO, July 30, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2012 second quarter financial results on Monday, August 6, 2012 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Monday, August 6 at 5:00 p.m. ET. The call may be accessed by...
SAN DIEGO, July 25, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it has received regulatory authorization from the Environmental Protection Agency (EPA) to market its next-generation cellulase enzyme for non-food applications, including use as a biocatalyst to break down the guar-based gel used in hydraulic fracturing. This...
